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ABSTRACT
Introduction: The objective of this study was to
evaluate the effects of canagliflozin, a sodium
glucose co-transporter 2 inhibitor, on serum
magnesium in hypomagnesemic patients with
type 2 diabetes.
Methods: This post hoc analysis was based on
pooled data from four placebo-controlled stud-
ies of canagliflozin (N = 2313). The proportion
of patients with baseline serum magnesium
\0.74 mmol/L who achieved serum magnesium
C0.74 mmol/L at week 26 was evaluated.
Results: At week 26, canagliflozin 100 and
300 mg increased serum magnesium versus
placebo in patients with baseline serum
magnesium\0.74 mmol/L (17.0% and 19.0% vs
3.9%) and C0.74 mmol/L (4.9% and 7.0% vs
-1.4%). More patients with baseline serum
magnesium \0.74 mmol/L had serum magne-
sium C0.74 mmol/L at week 26 with canagli-
flozin 100 and 300 mg versus placebo (74.1%
and 80.6% vs 28.8%).
Conclusions: Canagliflozin was associated with
normalization of serum magnesium in hypo-
magnesemic patients with type 2 diabetes,
potentially leading to improved car-
diometabolic outcomes.




Cardiovascular disease; Magnesium; Sodium
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INTRODUCTION
Many patients with type 2 diabetes have hypo-
magnesemia (serum magnesium\0.74 mmol/L);
poor intestinal absorption and renal wasting of
magnesium have been implicated in the
pathophysiology [1]. Hypomagnesemic patients
with type 2 diabetes show more rapid disease
progression and decline in renal function than
those with normal magnesium levels, and they
are at increased risk for cardiometabolic com-
plications and chronic kidney disease (CKD)
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[1–3]. Hypomagnesemic patients with type 2
diabetes have reduced pancreatic b-cell activity
and increased insulin resistance, which, in turn,
lower serum magnesium levels as part of a
‘‘vicious circle’’ [1]. Hypomagnesemia is also an
established risk factor for ventricular arrhyth-
mia, which may be an indicator of future car-
diovascular events or sudden cardiac death [4].
Increased magnesium levels have been shown
to mitigate cardiovascular risk [5, 6].
In a systematic review and meta-analysis of
randomized controlled trials, every 0.2 mmol/L
increase in circulating magnesium was associ-
ated with a 30% reduction in cardiovascular
disease risk; there was also a trend toward lower
risks of ischemic heart disease and fatal
ischemic heart disease [5]. A separate
meta-analysis demonstrated that increased
dietary magnesium intake was associated with a
decreased risk of heart failure and stroke [6].
The sodium glucose co-transporter 2 (SGLT2)
inhibitor canagliflozin has demonstrated clini-
cally meaningful improvements in glycemic
control, body weight, and blood pressure, with
a favorable tolerability profile in patients with
type 2 diabetes [7]. Canagliflozin has also been
shown to increase serum magnesium levels [8],
with minimal changes in its fractional excretion
[9]. We evaluated the effects of canagliflozin on




This post hoc analysis was based on pooled data
from four 26-week, placebo-controlled, phase 3
studies (N = 2313) that evaluated canagliflozin




Percentage change in serum magnesium at
week 26 was evaluated in patients with baseline
serum magnesium \0.74 and C0.74 mmol/L
using data obtained from standard laboratory
assessments during the individual trials. The
proportion of patients with baseline serum
magnesium\0.74 mmol/L who achieved serum
magnesium C0.74 mmol/L at week 26 was
determined.
Statistical Analyses
Data were from the modified intent-to-treat
population (mITT), which consisted of all ran-
domized patients who received C1 dose of
study drug. The last observation carried forward
approach was used to impute missing data at
week 26. Percentage change from baseline in
serum magnesium was analyzed using an
analysis of covariance (ANCOVA) model, with
treatment and study as fixed effects and the
corresponding baseline serum magnesium
value as a covariate. The model included terms
for treatment (to assess treatment effect), base-
line (to adjust for baseline differences), and
study (to account for differences in the studies
as the analysis was based on pooled data). Least
squares (LS) mean differences and two-sided
95% confidence intervals (CIs) were deter-
mined for each canagliflozin dose versus pla-
cebo. The categorical endpoint of the
proportion of hypomagnesemic patients with
serum magnesium \0.74 mmol/L at baseline
who achieved serum magnesium C0.74 mmol/
L at week 26 was analyzed using a logistic
regression model, with treatment and study as
fixed effects and baseline serum magnesium
value as a covariate. Odds ratios (ORs) and 95%
CIs were estimated for the proportion of
hypomagnesemic patients whose serum mag-
nesium levels normalized at week 26 with
canagliflozin versus placebo. Statistical testing
of differences between canagliflozin and pla-
cebo was not prespecified for these analyses;
therefore, P values are not reported.
Compliance with Ethics Guidelines
All study procedures followed were in accor-
dance with the ethical standards of the
responsible committee on human experimen-
tation (institutional and national) and with the
Helsinki Declaration of 1964, as revised in 2013.
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Informed consent was obtained from all
patients prior to their enrollment in the study.
RESULTS
Patients
Of 2313 patients in the mITT analysis set, mean
baseline serum magnesium was 0.78 mmol/L
(range 0.41–1.23 mmol/L [1–3 mg/dL]). In the
overall population, 18.3% (n = 424) had serum
magnesium \0.74 mmol/L (\1.8 mg/dL; hypo-
magnesemia), 80.7% (n = 1867) had serum
magnesium 0.74–0.94 mmol/L (1.8–2.3 mg/dL;
normal magnesium), and 1.0% (n = 22) had
serum magnesium[0.94 mmol/L ([2.3 mg/dL;
hypermagnesemia) at baseline; proportions
were generally similar with canagliflozin 100
and 300 mg and placebo, respectively, in each
serum magnesium category (hypomagnesemia:
20.2%, 16.9%, and 17.8%; normal magnesium:
78.8%, 82.3%, and 81.3%; hypermagnesemia:
1.1%, 0.8%, and 0.9%). Baseline characteristics
were generally balanced across groups in
patients with baseline serum magnesium\0.74
and C0.74 mmol/L (because of the small num-
ber of patients with hypermagnesemia, data for
all patients with serum magnesium
C0.74 mmol/L were pooled; Table 1).
Effects on Serum Magnesium
In the overall population, LS mean percentage
changes from baseline in serum magnesium at
week 26 were 8.1% and 9.3% with canagliflozin
100 and 300 mg versus -0.4% with placebo [8].
Among patients with baseline serum magne-
sium\0.74 mmol/L, LS mean percentage chan-
ges in serum magnesium at week 26 were
17.0%, 19.0%, and 3.9% with canagliflozin 100
and 300 mg and placebo, respectively (differ-
ences [95% CI] vs placebo of 13.0% [10.5, 15.6]
and 15.1% [12.4, 17.7]; Fig. 1). Among patients
with baseline serum magnesium C0.74 mmol/L,
LS mean percentage changes in serum magne-
sium were 4.9%, 7.0%, and -1.4% with cana-
gliflozin 100 and 300 mg and placebo,
respectively (differences [95% CI] of 6.3% [5.5,
7.2] and 8.4% [7.6, 9.2]; Fig. 1). There were no
patients with serum magnesium levels above
the upper limit of normal ([1.27 mmol/L) in
any treatment group at 26 weeks.
At week 26 in the canagliflozin 100 and
300 mg and placebo groups, 59 (7.2%), 33
(4.0%), and 117 (18.6%) patients had hypo-
magnesemia; 731 (88.7%), 738 (90.3%), and 505
(80.4%) patients had normal serum magnesium
levels; and 34 (4.1%), 46 (5.6%), and 6 (1.0%)
patients had hypermagnesemia, respectively.
Overall, a higher proportion of patients with
baseline serum magnesium\0.74 mmol/L had
serum magnesium C0.74 mmol/L at week 26
with canagliflozin 100 and 300 mg versus pla-
cebo (74.1%, 80.6%, and 28.8%, respectively;
Fig. 2). For hypomagnesemic patients, the like-
lihood of achieving serum magnesium
C0.74 mmol/L was 10 and 14 times greater with
canagliflozin 100 and 300 mg versus placebo.
DISCUSSION
Hypomagnesemia is common in patients with
type 2 diabetes (14–48%) and has been identi-
fied as an independent risk factor for cardio-
vascular disease and CKD [1–3]. In particular,
hypomagnesemic individuals can develop ven-
tricular arrhythmias, which may lead to serious
cardiovascular outcomes, including sudden
cardiac death [4, 10–12]. Evidence suggests that
increases in circulating magnesium are associ-
ated with a lower risk of cardiovascular disease;
this may be related to antiarrhythmic and
anti-ischemic effects in the heart, as well as
beneficial effects on endothelial tissue and vas-
cular smooth muscle cells (e.g., enhanced
vasodilation, reduced inflammation) [5]. In this
analysis, canagliflozin treatment increased
serum magnesium over 26 weeks and normal-
ized magnesium levels in hypomagnesemic
patients with type 2 diabetes.
Results from the current analysis are consis-
tent with a recent meta-analysis of 18 random-
ized controlled trials of SGLT2 inhibitors in
patients with type 2 diabetes, suggesting that
the impact on serum magnesium levels may be
a class effect [13]. Dose-dependent increases in
magnesium were seen with canagliflozin 100
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and 300 mg (0.06 vs 0.09 mmol/L); similar
changes were observed with dapagliflozin
10 mg (0.1 mmol/L), empagliflozin 10 and
25 mg (0.04 vs 0.07 mmol/L), and ipragliflozin
50 mg (0.05 mmol/L) [13]. Of note, the
meta-analysis results were based on data from
patients with normal renal function, but a sen-
sitivity analysis including data from two trials
in patients with CKD showed that the overall
findings were robust [13]. Canagliflozin has also
demonstrated serum magnesium improvements
in patients with type 2 diabetes and CKD
(eGFR C30 and\50 mL/min/1.73 m2) [14, 15].
Over 26 weeks of treatment, increases in serum
magnesium were seen with canagliflozin 100
and 300 mg (9.4% vs 14.6%), whereas no
change was seen with placebo (0.0%; baseline,
0.8 mmol/L for all) [14].
Abnormal elevations of serum magnesium
have been linked to adverse cardiovascular
outcomes in certain populations (e.g., heart
failure, critically ill, or on hemodialysis)
[16–18]. In this analysis, there was a small
increase from baseline in the number of
patients with hypermagnesemia in the canagli-
flozin groups at week 26, but no patients had
serum magnesium levels above the upper limit
of normal ([1.27 mmol/L). It is important to
note that canagliflozin is not indicated for use
in patients with severe renal impairment or
end-stage renal disease or who are on dialysis
[19].
The mechanism for the observed effects of
canagliflozin on serum magnesium is unclear. It
is unlikely that the increases in serum magne-
sium seen with canagliflozin are attributable to
glycemic improvements, as increases in serum
magnesium have not been reported with other
antihyperglycemic agents, including sitagliptin
and glimepiride, in head-to-head studies with
canagliflozin (data on file and [20]). A possible
explanation is that canagliflozin treatment is
associated with improvements in insulin sensi-
tivity (measured by changes in glucosuria-
corrected oral glucose insulin sensitivity [OGISc]
index values [21]), which may increase magne-
sium levels by interrupting the cycle of hypo-
magnesemia induced by insulin resistance. And
while bone storage is involved in magnesium
homeostasis, it is unlikely that increased mag-
nesium levels are due to leaching from bone, as
bone mineral density remains relatively
unchanged with canagliflozin treatment over
2 years [22]. Another consideration is that SGLT2
inhibitors have been shown to increase plasma
glucagon levels [23, 24], which may increase
magnesium reabsorption in the distal convo-
luted tubule (DCT) [25]. Finally, the observed
increase in serum magnesium may be related to
canagliflozin acting on ion channels in the DCT
(e.g., TRPM6/TRPM7), which have been found to
modulate urinary magnesium excretion [26].
Fig. 1 Percentage change from baseline in serum magne-
sium at week 26. Mg magnesium, CI conﬁdence interval,
LS least squares, SE standard error, PBO placebo, CANA
canagliﬂozin
Fig. 2 Proportion of patients with baseline serum mag-
nesium \0.74 mmol/L who achieved serum magnesium
C0.74 mmol/L at week 26. OR odds ratio, CI conﬁdence
interval, PBO placebo, CANA canagliﬂozin
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This analysis was strengthened by the use of
a large, pooled dataset. At baseline, approxi-
mately 18% of patients were hypomagnesemic,
which is representative of the general type 2
diabetes population [1]. One potential limita-
tion of this analysis was that there were no
restrictions on the use of drugs known to alter
magnesium homeostasis (e.g., diuretics, proton
pump inhibitors, antimicrobials) [1], which
may have impacted serum magnesium levels.
However, canagliflozin treatment has demon-
strated consistent increases in serum magne-
sium across a broad range of patients with type
2 diabetes with varying degrees of background
diuretic use, including the current analysis
(approximately 23% of patients were on
diuretics) and a separate analysis of patients
with eGFR C45 and \60 mL/min/1.73 m2 (ap-
proximately 50% of patients were on diuretics)
[8]. Another potential limitation was that
intracellular magnesium levels were not mea-
sured. Intracellular magnesium has been pro-
posed to better reflect magnesium homeostasis
than serum magnesium, as approximately 99%
of magnesium is stored within bone, muscle,
and other soft tissues; however, serum magne-
sium remains widely used and may be a more
practical measure for clinicians who treat
patients with type 2 diabetes.
CONCLUSIONS
Canagliflozin was associated with normaliza-
tion of serum magnesium levels in hypomag-
nesemic patients with type 2 diabetes, which
may lead to improved cardiometabolic out-
comes and a reduced risk of arrhythmia. Results
from ongoing, large-scale outcomes trials will
help to define the potential benefits of canagli-
flozin on cardiovascular health and risk of CKD.
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